bluuebunny/crossref_metadata_2025 huggingface dataset:
Data from Nkx2.8 Inhibits Epithelial–Mesenchymal Transition in Bladder Urothelial Carcinoma via Transcriptional Repression of Twist1
Authors: Yu Chunping , Liu Zhuowei , Chen Qiuhong , Li Yonghong , Jiang Lijuan , Zhang Zhiling , Zhou Fangjian
Published: April 2023

Abstract
Epithelial-to-mesenchymal transition (EMT) promotes metastasis, which is the main cause of bladder urothelial carcinoma–related death. Loss of the candidate tumor-suppressor gene Nkx2.8 has been associated with urothelial carcinoma lymph node metastasis. Here, we show that enforced expression of Nkx2.8 is sufficient to inhibit EMT, reduce motility, and blunt invasiveness of urothelial carcinoma cells. Mechanistic investigations showed that Nkx2.8 negatively regulated expression of the EMT inducer Twist1 in urothelial carcinoma cells, at both the level of mRNA and protein accumulation. Nkx2.8 bound directly to the promoter region of this gene and transcriptionally repressed its expression. Twist1 upregulation reversed EMT inhibition by Nkx2.8, restoring the invasive phenotype of urothelial carcinoma cells. In clinical urothelial carcinoma specimens, expression of Nkx2.8 inversely correlated with Twist1 expression, and urothelial carcinoma patients with Nkx2.8 positivity and low Twist1 expression displayed the best prognosis. Our findings highlight the Nkx2.8–Twist1 axis as candidate target for therapeutic intervention in advanced urothelial carcinoma.

Significance: These findings highlight a novel EMT signaling axis as a candidate target for therapeutic intervention in advanced urothelial carcinomas. Cancer Res; 78(5); 1241–52. ©2018 AACR.
Data from Brain-Mimetic 3D Culture Platforms Allow Investigation of Cooperative Effects of Extracellular Matrix Features on Therapeutic Resistance in Glioblastoma
Authors: Xiao Weikun , Zhang Rongyu , Sohrabi Alireza , Ehsanipour Arshia , Sun Songping , Liang Jesse , Walthers Christopher M. , Ta Lisa , Nathanson David A. , Seidlits Stephanie K.
Published: April 2023

Abstract
Glioblastoma (GBM) tumors exhibit potentially actionable genetic alterations against which targeted therapies have been effective in treatment of other cancers. However, these therapies have largely failed in GBM patients. A notable example is kinase inhibitors of EGFR, which display poor clinical efficacy despite overexpression and/or mutation of EGFR in >50% of GBM. In addressing this issue, preclinical models may be limited by the inability to accurately replicate pathophysiologic interactions of GBM cells with unique aspects of the brain extracellular matrix (ECM), which is relatively enriched in hyaluronic acid (HA) and flexible. In this study, we present a brain-mimetic biomaterial ECM platform for 3D culturing of patient-derived GBM cells, with improved pathophysiologic properties as an experimental model. Compared with orthotopic xenograft assays, the novel biomaterial cultures we developed better preserved the physiology and kinetics of acquired resistance to the EGFR inhibition than gliomasphere cultures. Orthogonal modulation of both HA content and mechanical properties of biomaterial scaffolds was required to achieve this result. Overall, our findings show how specific interactions between GBM cell receptors and scaffold components contribute significantly to resistance to the cytotoxic effects of EGFR inhibition.

Significance: Three-dimensional culture scaffolds of glioblastoma provide a better physiological representation over current methods of patient-derived cell culture and xenograft models. Cancer Res; 78(5); 1358–70. ©2017 AACR.
Data from A KDM5 Inhibitor Increases Global H3K4 Trimethylation Occupancy and Enhances the Biological Efficacy of 5-Aza-2′-Deoxycytidine
Authors: Leadem Benjamin R. , Kagiampakis Ioannis , Wilson Catherine , Cheung Tommy K. , Arnott David , Trojer Patrick , Classon Marie , Easwaran Hariharan , Baylin Stephen B.
Published: April 2023

Abstract
The H3K4 demethylase KDM5B is amplified and overexpressed in luminal breast cancer, suggesting it might constitute a potential cancer therapy target. Here, we characterize, in breast cancer cells, the molecular effects of a recently developed small-molecule inhibitor of the KDM5 family of proteins (KDM5i), either alone or in combination with the DNA-demethylating agent 5-aza-2′-deoxycytidine (DAC). KDM5i treatment alone increased expression of a small number of genes, whereas combined treatment with DAC enhanced the effects of the latter for increasing expression of hundreds of DAC-responsive genes. ChIP-seq studies revealed that KDM5i resulted in the broadening of existing H3K4me3 peaks. Furthermore, cells treated with the drug combination exhibited increased promoter and gene body H3K4me3 occupancy at DAC-responsive genes compared with DAC alone. Importantly, treatment with either DAC or DAC+KDM5i induced a dramatic increase in H3K27ac at enhancers with an associated significant increase in target gene expression, suggesting a previously unappreciated effect of DAC on transcriptional regulation. KDM5i synergized with DAC to reduce the viability of luminal breast cancer cells in in vitro assays. Our study provides the first look into the molecular effects of a novel KDM5i compound and suggests that combinatorial inhibition along with DAC represents a new area to explore in translational epigenetics.

Significance: This study offers a first look into the molecular effects of a novel KDM5 inhibitory compound, suggesting how its use in combination with DNA methylation inhibitors presents new opportunities to explore in translational cancer epigenetics. Cancer Res; 78(5); 1127–39. ©2017 AACR.
Supplementary Table 2 from A Pooled Analysis of Alcohol Consumption and Risk of Multiple Myeloma in the International Multiple Myeloma Consortium
Authors: Andreotti Gabriella , Birmann Brenda , De Roos Anneclaire J. , Spinelli John , Cozen Wendy , Camp Nicola J. , Moysich Kirsten , Chiu Brian , Steplowski Emily , Krzystan Joseph , Boffetta Paolo , Benhaim-Luzon Véronique , Brennan Paul , de Sanjosé Silvia , Costas Laura , Costantini Adele Seniori , Miligi Lucia , Cocco Pierluigi , Becker Nikolaus , Foretová Lenka , Maynadié Marc , Nieters Alexandra , Staines Anthony , Tricot Guido , Milliken Kevin , Weisenburger Dennis , Zheng Tongzhang , Baris Dalsu , Purdue Mark P.
Published: April 2023

PDF - 53KB, Risk of Multiple Myeloma associated with alcohol consumption in pooled study population by ever and former drinkers.
Data from A Pilot Randomized Controlled Trial of the Feasibility, Acceptability, and Impact of Giving Information on Personalized Genomic Risk of Melanoma to the Public
Authors: Smit Amelia K. , Espinoza David , Newson Ainsley J. , Morton Rachael L. , Fenton Georgina , Freeman Lucinda , Dunlop Kate , Butow Phyllis N. , Law Matthew H. , Kimlin Michael G. , Keogh Louise A. , Dobbinson Suzanne J. , Kirk Judy , Kanetsky Peter A. , Mann Graham J. , Cust Anne E.
Published: April 2023

Abstract
Background: Communication of personalized melanoma genomic risk information may improve melanoma prevention behaviors.

Methods: We evaluated the feasibility and acceptability of communicating personalized genomic risk of melanoma to the public and its preliminary impact on behaviors and psychosocial outcomes. One hundred eighteen people aged 22 to 69 years provided a saliva sample and were randomized to the control (nonpersonalized educational materials) or intervention (personalized booklet presenting melanoma genomic risk as absolute and relative risks and a risk category based on variants in 21 genes, telephone-based genetic counseling, and nonpersonalized educational materials). Intention-to-treat analyses overall and by-risk category were conducted using ANCOVA adjusted for baseline values.

Results: Consent to participate was 41%, 99% were successfully genotyped, and 92% completed 3-month follow-up. Intervention participants reported high satisfaction with the personalized booklet (mean = 8.6, SD = 1.6; on a 0–10 scale) and genetic counseling (mean = 8.1, SD = 2.2). No significant behavioral effects at 3-month follow-up were identified between intervention and control groups overall: objectively measured standard erythemal doses per day [−16%; 95% confidence interval (CI), −43% to 24%] and sun protection index (0.05; 95% CI, −0.07 to 0.18). There was increased confidence identifying melanoma at 3 months (0.40; 95% CI, 0.10–0.69). Stratified by risk category, effect sizes for intentional tanning and some individual sun protection items appeared stronger for the average-risk group. There were no appreciable group differences in skin cancer–related worry or psychologic distress.

Conclusions: Our results demonstrate feasibility and acceptability of providing personalized genomic risk of melanoma to the public.

Impact: Genomic risk information has potential as a melanoma prevention strategy. Cancer Epidemiol Biomarkers Prev; 26(2); 212–21. ©2016 AACR.
Data from Racial Variation in Breast Tumor Promoter Methylation in the Carolina Breast Cancer Study
Authors: Conway Kathleen , Edmiston Sharon N. , Tse Chiu-Kit , Bryant Christopher , Kuan Pei Fen , Hair Brionna Y. , Parrish Eloise A. , May Ryan , Swift-Scanlan Theresa
Published: April 2023

Abstract
Background: African American (AA) women are diagnosed with more advanced breast cancers and have worse survival than white women, but a comprehensive understanding of the basis for this disparity remains unclear. Analysis of DNA methylation, an epigenetic mechanism that can regulate gene expression, could help to explain racial differences in breast tumor clinical biology and outcomes.

Methods: DNA methylation was evaluated at 1,287 CpGs in the promoters of cancer-related genes in 517 breast tumors of AA (n = 216) or non-AA (n = 301) cases in the Carolina Breast Cancer Study (CBCS).

Results: Multivariable linear regression analysis of all tumors, controlling for age, menopausal status, stage, intrinsic subtype, and multiple comparisons [false discovery rate (FDR)], identified seven CpG probes that showed significant (adjusted P < 0.05) differential methylation between AAs and non-AAs. Stratified analyses detected an additional four CpG probes differing by race within hormone receptor–negative (HR−) tumors. Genes differentially methylated by race included DSC2, KCNK4, GSTM1, AXL, DNAJC15, HBII-52, TUSC3, and TES; the methylation state of several of these genes may be associated with worse survival in AAs. TCGA breast tumor data confirmed the differential methylation by race and negative correlations with expression for most of these genes. Several loci also showed racial differences in methylation in peripheral blood leukocytes (PBL) from CBCS cases, indicating that these variations were not necessarily tumor-specific.

Conclusions: Racial differences in the methylation of cancer-related genes are detectable in both tumors and PBLs from breast cancer cases.

Impact: Epigenetic variation could contribute to differences in breast tumor development and outcomes between AAs and non-AAs. Cancer Epidemiol Biomarkers Prev; 24(6); 921–30. ©2015 AACR.
Data from Low-Coverage Exome Sequencing Screen in Formalin-Fixed Paraffin-Embedded Tumors Reveals Evidence of Exposure to Carcinogenic Aristolochic Acid
Authors: Castells Xavier , Karanović Sandra , Ardin Maude , Tomić Karla , Xylinas Evanguelos , Durand Geoffroy , Villar Stephanie , Forey Nathalie , Le Calvez-Kelm Florence , Voegele Catherine , Karlović Krešimir , Mišić Maja , Dittrich Damir , Dolgalev Igor , McKay James , Shariat Shahrokh F. , Sidorenko Viktoria S. , Fernandes Andrea , Heguy Adriana , Dickman Kathleen G. , Olivier Magali , Grollman Arthur P. , Jelaković Bojan , Zavadil Jiri
Published: April 2023

Abstract
Background: Dietary exposure to cytotoxic and carcinogenic aristolochic acid (AA) causes severe nephropathy typically associated with urologic cancers. Monitoring of AA exposure uses biomarkers such as aristolactam-DNA adducts, detected by mass spectrometry in the kidney cortex, or the somatic A>T transversion pattern characteristic of exposure to AA, as revealed by previous DNA-sequencing studies using fresh-frozen tumors.

Methods: Here, we report a low-coverage whole-exome sequencing method (LC-WES) optimized for multisample detection of the AA mutational signature, and demonstrate its utility in 17 formalin-fixed paraffin-embedded urothelial tumors obtained from 15 patients with endemic nephropathy, an environmental form of AA nephropathy.

Results: LC-WES identified the AA signature, alongside signatures of age and APOBEC enzyme activity, in 15 samples sequenced at the average per-base coverage of approximately 10×. Analysis at 3 to 9× coverage revealed the signature in 91% of the positive samples. The exome-wide distribution of the predominant A>T transversions exhibited a stochastic pattern, whereas 83 cancer driver genes were enriched for recurrent nonsynonymous A>T mutations. In two patients, pairs of tumors from different parts of the urinary tract, including the bladder, harbored overlapping mutation patterns, suggesting tumor dissemination via cell seeding.

Conclusions: LC-WES analysis of archived tumor tissues is a reliable method applicable to investigations of both the exposure to AA and its biologic effects in human carcinomas.

Impact: By detecting cancers associated with AA exposure in high-risk populations, LC-WES can support future molecular epidemiology studies and provide evidence-base for relevant preventive measures. Cancer Epidemiol Biomarkers Prev; 24(12); 1873–81. ©2015 AACR.
Data from A Novel Pathway-Based Approach Improves Lung Cancer Risk Prediction Using Germline Genetic Variations
Authors: Qian David C. , Han Younghun , Byun Jinyoung , Shin Hae Ri , Hung Rayjean J. , McLaughlin John R. , Landi Maria Teresa , Seminara Daniela , Amos Christopher I.
Published: April 2023

Abstract
Background: Although genome-wide association studies (GWAS) have identified many genetic variants that are strongly associated with lung cancer, these variants have low penetrance and serve as poor predictors of lung cancer in individuals. We sought to increase the predictive value of germline variants by considering their cumulative effects in the context of biologic pathways.

Methods: For individuals in the Environment and Genetics in Lung Cancer Etiology study (1,815 cases/1,971 controls), we computed pathway-level susceptibility effects as the sum of relevant SNP variant alleles weighted by their log-additive effects from a separate lung cancer GWAS meta-analysis (7,766 cases/37,482 controls). Logistic regression models based on age, sex, smoking, genetic variants, and principal components of pathway effects and pathway–smoking interactions were trained and optimized in cross-validation and further tested on an independent dataset (556 cases/830 controls). We assessed prediction performance using area under the receiver operating characteristic curve (AUC).

Results: Compared with typical binomial prediction models that have epidemiologic predictors (AUC = 0.607) in addition to top GWAS variants (AUC = 0.617), our pathway-based smoking-interactive multinomial model significantly improved prediction performance in external validation (AUC = 0.656, P < 0.0001).

Conclusions: Our biologically informed approach demonstrated a larger increase in AUC over nongenetic counterpart models relative to previous approaches that incorporate variants.

Impact: This model is the first of its kind to evaluate lung cancer prediction using subtype-stratified genetic effects organized into pathways and interacted with smoking. We propose pathway–exposure interactions as a potentially powerful new contributor to risk inference. Cancer Epidemiol Biomarkers Prev; 25(8); 1208–15. ©2016 AACR.
Data from The Prevalence of Cancer-Associated Autoantibodies in Patients with Gastric Cancer and Progressive Grades of Premalignant Lesions
Authors: Meistere Irēna , Werner Simone , Zayakin Pawel , Siliņa Karīna , Rulle Undīne , Pismennaja Angelina , Šantare Daiga , Kikuste Ilze , Isajevs Sergejs , Leja Mārcis , Kupčinskas Limas , Kupčinskas Juozas , Jonaitis Laimas , Wu Chun-Ying , Brenner Hermann , Linē Aija , Kalniņa Zane
Published: April 2023

Abstract
Background: Serum autoantibodies against tumor-associated antigens (TAAs) are detectable in early-stage gastric cancer patients; however, the time point during cancerogenesis when they appear in circulation is still obscure.

Methods: In this study, we developed a recombinant antigen microarray and analyzed the prevalence of autoantibodies against 102 TAAs in 829 gastric cancer patients and 929 healthy controls from Caucasian and Asian populations, as well as 100 patients with chronic atrophic gastritis and 775 individuals staged according to different grades of intestinal metaplasia.

Results: Six antigens, including CTAG1B/CTAG2, DDX53, IGF2BP2, TP53, and MAGEA3, were predominantly reacting with sera from gastric cancer patients when compared with healthy controls, and the seroreactivity was associated with intestinal-type gastric cancer, but not with patients' Helicobacter pylori status, grade, age, gender, or stage of gastric cancer. We detected gastric cancer–associated seroreactivity in 13% of patients with advanced/severe intestinal metaplasia, which was increased in comparison with mild/moderate intestinal metaplasia (5.3%) and was comparable with that seen in early-stage gastric cancer patients (12%). Moreover, by testing serum samples taken 1 to 9 years before the clinical diagnosis of 18 incident gastric cancer cases, we detected autoantibody responses against several TAAs—SOX2, MYC, BIRC5, IGF2BP1, and MUC1.

Conclusions: Our results suggest that humoral immune response against TAAs is generated already during premalignant stages.

Impact: Based on the obtained results, cancer-associated autoantibodies might make a valuable contribution to the stratification of high-risk patients with premalignant lesions in the stomach through enhancing the positive predictive power of existing risk models. Cancer Epidemiol Biomarkers Prev; 26(10); 1564–74. ©2017 AACR.
Data from Inflammatory Markers of CRP, IL6, TNFα, and Soluble TNFR2 and the Risk of Ovarian Cancer: A Meta-analysis of Prospective Studies
Authors: Zeng Fangfang , Wei Huishan , Yeoh Engkiong , Zhang Zheqing , Ren Ze-Fang , Colditz Graham A. , Tworoger Shelley S. , Su Xuefen
Published: April 2023

Abstract
Background: There has been growing evidence showing that inflammatory markers play an important role in the development of ovarian cancer. We conducted a meta-analysis on the associations between circulating levels of C-reactive protein (CRP), interleukin 6 (IL6), tumor necrosis factor α (TNFα), and soluble TNFα receptor 2 (TNFR2), and the risk of ovarian cancer.

Methods: A systematic search of PubMed and EMBASE up until January 19, 2016 was conducted to retrieve prospective studies. The summary risk estimates were pooled using random-effects models. The dose–response relationship was assessed using generalized least-squares trend estimation.

Results: Seven nested case–control studies and one prospective cohort study were included in the review. For circulating CRP, women in the highest category had a significantly increased risk of ovarian cancer than women in the lowest category, with no significant between-study heterogeneity [pooled relative risk (RR) = 1.91; 95% confidence intervals (CI) 1.51–2.40; P < 0.001; I2 = 0.0%]. Influence analyses further supported this positive association. A positive dose–response relationship was also observed (pooled RR = 1.15; 95% CI, 1.03–1.30 per 5 mg/L of CRP). Publication bias was found. However, the association persisted after correction using the trim-and-fill method. No significant association was observed for circulating IL6, TNFα, and soluble TNFR2.

Conclusion: This meta-analysis provides evidence that elevated levels of CRP, but not circulating IL6, TNFα, or soluble TNFR2, are significantly associated with an increased risk of ovarian cancer.

Impact: These results suggest that circulating CRP may play a role in the etiology of ovarian cancer. Cancer Epidemiol Biomarkers Prev; 25(8); 1231–9. ©2016 AACR.
Data from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes
Authors: Ko Jennifer S. , Matharoo-Ball Balwir , Billings Steven D. , Thomson Brian J. , Tang Jean Y. , Sarin Kavita Y. , Cai Emily , Kim Jinah , Rock Colleen , Kimbrell Hillary Z. , Flake Darl D. , Warf M. Bryan , Nelson Jonathan , Davis Thaylon , Miller Catherine , Rushton Kristen , Hartman Anne-Renee , Wenstrup Richard J. , Clarke Loren E.
Published: April 2023

Abstract
Background: Histopathologic examination alone can be inadequate for diagnosis of certain melanocytic neoplasms. Recently, a 23-gene expression signature was clinically validated as an ancillary diagnostic test to differentiate benign nevi from melanoma. The current study assessed the performance of this test in an independent cohort of melanocytic lesions against clinically proven outcomes.

Methods: Archival tissue from primary cutaneous melanomas and melanocytic nevi was obtained from four independent institutions and tested with the gene signature. Cases were selected according to pre-defined clinical outcome measures. Malignant lesions were defined as stage I–III primary cutaneous melanomas that produced distant metastases (metastatic to sites other than proximal sentinel lymph node(s)) following diagnosis of the primary lesion. Melanomas that were metastatic at the time of diagnosis, all re-excisions, and lesions with <10% tumor volume were excluded. Benign lesions were defined as cutaneous melanocytic lesions with no adverse long-term events reported.

Results: Of 239 submitted samples, 182 met inclusion criteria and produced a valid gene expression result. This included 99 primary cutaneous melanomas with proven distant metastases and 83 melanocytic nevi. Median time to melanoma metastasis was 18 months. Median follow-up time for nevi was 74.9 months. The gene expression score differentiated melanoma from nevi with a sensitivity of 93.8% and a specificity of 96.2%.

Conclusions: The results of gene expression testing closely correlate with long-term clinical outcomes of patients with melanocytic neoplasms.

Impact: Collectively, this provides strong evidence that the gene signature adds valuable adjunctive information to aid in the accurate diagnosis of melanoma. Cancer Epidemiol Biomarkers Prev; 26(7); 1107–13. ©2017 AACR.
Data from Maté Drinking and Esophageal Squamous Cell Carcinoma in South America: Pooled Results from Two Large Multicenter Case–Control Studies
Authors: Lubin Jay H. , De Stefani Eduardo , Abnet Christian C. , Acosta Gisele , Boffetta Paolo , Victora Cesar , Graubard Barry I. , Muñoz Nubia , Deneo-Pellegrini Hugo , Franceschi Silvia , Castellsagué Xavier , Ronco Alvaro L. , Dawsey Sanford M.
Published: April 2023

Abstract
Background: Maté tea is a nonalcoholic infusion widely consumed in southern South America, and may increase risk of esophageal squamous cell carcinoma (ESCC) and other cancers due to polycyclic aromatic hydrocarbons (PAH) and/or thermal injury.

Methods: We pooled two case–control studies: a 1988 to 2005 Uruguay study and a 1986 to 1992 multinational study in Argentina, Brazil, Paraguay, and Uruguay, including 1,400 cases and 3,229 controls. We computed ORs and fitted a linear excess OR (EOR) model for cumulative maté consumption in liters/day–year (LPDY).

Results: The adjusted OR for ESCC with 95% confidence interval (CI) by ever compared with never use of maté was 1.60 (1.2–2.2). ORs increased linearly with LPDY (test of nonlinearity; P = 0.69). The estimate of slope (EOR/LPDY) was 0.009 (0.005–0.014) and did not vary with daily intake, indicating maté intensity did not influence the strength of association. EOR/LPDY estimates for consumption at warm, hot, and very hot beverage temperatures were 0.004 (−0.002–0.013), 0.007 (0.003–0.013), and 0.016 (0.009–0.027), respectively, and differed significantly (P < 0.01). EOR/LPDY estimates were increased in younger (<65) individuals and never alcohol drinkers, but these evaluations were post hoc, and were homogeneous by sex.

Conclusions: ORs for ESCC increased linearly with cumulative maté consumption and were unrelated to intensity, so greater daily consumption for shorter duration or lesser daily consumption for longer duration resulted in comparable ORs. The strength of association increased with higher maté temperatures.

Impact: Increased understanding of cancer risks with maté consumption enhances the understanding of the public health consequences given its purported health benefits. Cancer Epidemiol Biomarkers Prev; 23(1); 107–16. ©2013 AACR.
Supplementary Data from β2-Microglobulin Signaling Blockade Inhibited Androgen Receptor Axis and Caused Apoptosis in Human Prostate Cancer Cells
Authors: Huang Wen-Chin , Havel Jonathan J. , Zhau Haiyen E. , Qian Wei Ping , Lue Hui-Wen , Chu Chia-Yi , Nomura Takeo , Chung Leland W.K.
Published: April 2023

Supplementary Data from β2-Microglobulin Signaling Blockade Inhibited Androgen Receptor Axis and Caused Apoptosis in Human Prostate Cancer Cells
Supplementary Figures S1-S3 from Radiotherapy Decreases Vascular Density and Causes Hypoxia with Macrophage Aggregation in TRAMP-C1 Prostate Tumors
Authors: Chen Fang-Hsin , Chiang Chi-Shiun , Wang Chun-Chieh , Tsai Chien-Sheng , Jung Shih-Ming , Lee Chung-Chi , McBride William H. , Hong Ji-Hong
Published: April 2023

Supplementary Figures S1-S3 from Radiotherapy Decreases Vascular Density and Causes Hypoxia with Macrophage Aggregation in TRAMP-C1 Prostate Tumors
Supplementary Figure 4 from Metabolic Imaging: A Link between Lactate Dehydrogenase A, Lactate, and Tumor Phenotype
Authors: Serganova Inna , Rizwan Asif , Ni Xiaohui , Thakur Sunitha B. , Vider Jelena , Russell James , Blasberg Ronald , Koutcher Jason A.
Published: April 2023

PDF file - 1.05MB
Supplementary Figure 1 from Metadherin Promotes Hepatocellular Carcinoma Metastasis through Induction of Epithelial–Mesenchymal Transition
Authors: Zhu Kai , Dai Zhi , Pan Qi , Wang Zheng , Yang Guo-Huan , Yu Lei , Ding Zhen-Bin , Shi Guo-Ming , Ke Ai-Wu , Yang Xin-Rong , Tao Zhong-Hua , Zhao Yi-Ming , Qin Yi , Zeng Hai-Ying , Tang Zhao-You , Fan Jia , Zhou Jian
Published: April 2023

PDF file - 4.1MB
Supplementary Data 4 from Serum Autoantibody Signature of Ductal Carcinoma In Situ Progression to Invasive Breast Cancer
Authors: Mangé Alain , Lacombe Jérôme , Bascoul-Mollevi Caroline , Jarlier Marta , Lamy Pierre-Jean , Rouanet Philippe , Maudelonde Thierry , Solassol Jérôme
Published: April 2023

PDF file - 71K
Supplementary Table 1 from Infiltration of Lynch Colorectal Cancers by Activated Immune Cells Associates with Early Staging of the Primary Tumor and Absence of Lymph Node Metastases
Authors: de Miranda Noel F.C.C. , Goudkade Danny , Jordanova Ekaterina S. , Tops Carli M.J. , Hes Frederik J. , Vasen Hans F.A. , van Wezel Tom , Morreau Hans
Published: April 2023

PDF file - 28K
CCR Translation for This Article from A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer
Authors: Hong David S. , Kurzrock Razelle , Oh Yun , Wheler Jennifer , Naing Aung , Brail Les , Callies Sophie , André Valérie , Kadam Sunil K. , Nasir Aejaz , Holzer Timothy R. , Meric-Bernstam Funda , Fishman Mayer , Simon George
Published: April 2023

CCR Translation for This Article from A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer
Supplementary Methods, Figures 1 - 6, Tables 1 - 2 from Tumor-Associated Macrophages Promote Angiogenesis and Melanoma Growth via Adrenomedullin in a Paracrine and Autocrine Manner
Authors: Chen Peiwen , Huang Yujie , Bong Rosabel , Ding Yanping , Song Nan , Wang Xiaofeng , Song Xiaomin , Luo Yongzhang
Published: April 2023

PDF file - 324KB
Supplementary Table 1 from High XRCC1 Protein Expression Is Associated with Poorer Survival in Patients with Head and Neck Squamous Cell Carcinoma
Authors: Ang Mei-Kim , Patel Mihir R. , Yin Xiao-Ying , Sundaram Sneha , Fritchie Karen , Zhao Ni , Liu Yufeng , Freemerman Alex J. , Wilkerson Matthew D. , Walter Vonn , Weissler Mark C. , Shockley William W. , Couch Marion E. , Zanation Adam M. , Hackman Trevor , Chera Bhishamjit S. , Harris Stephen L. , Miller C. Ryan , Thorne Leigh B. , Hayward Michele C. , Funkhouser William K. , Olshan Andrew F. , Shores Carol G. , Makowski Liza , Hayes D. Neil
Published: April 2023

PDF file - 68KB
Supplementary Table 3 from An Apoptosis Methylation Prognostic Signature for Early Lung Cancer in the IFCT-0002 Trial
Authors: de Fraipont Florence , Levallet Guénaëlle , Creveuil Christian , Bergot Emmanuel , Beau-Faller Michèle , Mounawar Mounia , Richard Nicolas , Antoine Martine , Rouquette Isabelle , Favrot Marie-Christine , Debieuvre Didier , Braun Denis , Westeel Virginie , Quoix Elisabeth , Brambilla Elisabeth , Hainaut Pierre , Moro-Sibilot Denis , Morin Franck , Milleron Bernard , Zalcman Gérard
Published: April 2023

PDF file - 205K, Correlation between RASSF1 promoter gene methylation and RASSF1A protein expression by immunoblotting
Supplementary Figure 2 from Disruptive TP53 Mutation Is Associated with Aggressive Disease Characteristics in an Orthotopic Murine Model of Oral Tongue Cancer
Authors: Sano Daisuke , Xie Tong-Xin , Ow Thomas J. , Zhao Mei , Pickering Curtis R. , Zhou Ge , Sandulache Vlad C. , Wheeler David A. , Gibbs Richard A. , Caulin Carlos , Myers Jeffrey N.
Published: April 2023

PDf file - 418K
Supplementary Figure Legends 1-3 from Copy Number Gain of 1q25 Predicts Poor Progression-Free Survival for Pediatric Intracranial Ependymomas and Enables Patient Risk Stratification: A Prospective European Clinical Trial Cohort Analysis on Behalf of the Children's Cancer Leukaemia Group (CCLG), Société Française d'Oncologie Pédiatrique (SFOP), and International Society for Pediatric Oncology (SIOP)
Authors: Kilday John-Paul , Mitra Biswaroop , Domerg Caroline , Ward Jennifer , Andreiuolo Felipe , Osteso-Ibanez Teresa , Mauguen Audrey , Varlet Pascale , Le Deley Marie-Cecile , Lowe James , Ellison David W. , Gilbertson Richard J. , Coyle Beth , Grill Jacques , Grundy Richard G.
Published: April 2023

PDF file - 68K
Supplementary Figure 2 from Copy Number Gain of 1q25 Predicts Poor Progression-Free Survival for Pediatric Intracranial Ependymomas and Enables Patient Risk Stratification: A Prospective European Clinical Trial Cohort Analysis on Behalf of the Children's Cancer Leukaemia Group (CCLG), Société Française d'Oncologie Pédiatrique (SFOP), and International Society for Pediatric Oncology (SIOP)
Authors: Kilday John-Paul , Mitra Biswaroop , Domerg Caroline , Ward Jennifer , Andreiuolo Felipe , Osteso-Ibanez Teresa , Mauguen Audrey , Varlet Pascale , Le Deley Marie-Cecile , Lowe James , Ellison David W. , Gilbertson Richard J. , Coyle Beth , Grill Jacques , Grundy Richard G.
Published: April 2023

PDF file - 54K, Intracranial ependymoma demonstrating 1q gain on 500K SNP array analysis and 1q25 gain with iFISH.
Supplementary Methods, Table 1, Figures 1-6 from Inhibition of Collagen Receptor Discoidin Domain Receptor-1 (DDR1) Reduces Cell Survival, Homing, and Colonization in Lung Cancer Bone Metastasis
Authors: Valencia Karmele , Ormazábal Cristina , Zandueta Carolina , Luis-Ravelo Diego , Antón Iker , Pajares María J. , Agorreta Jackeline , Montuenga Luis M. , Martínez-Canarias Susana , Leitinger Birgit , Lecanda Fernando
Published: April 2023

PDF file - 409K
Supplementary Figures 1-4, Tables 1-7 from Progenitor-like Traits Contribute to Patient Survival and Prognosis in Oligodendroglial Tumors
Authors: Ng Felicia Soo-Lee , Toh Tan Boon , Ting Esther Hui-Ling , Koh Geraldene Rong-Hui , Sandanaraj Edwin , Phong Mark , Wong Swee Seong , Leong Siew Hong , Kon Oi Lian , Tucker-Kellogg Greg , Ng Wai Hoe , Ng Ivan , Tang Carol , Ang Beng Ti
Published: April 2023

PDF file - 688K, Supplementary Fig. S1. NNI-8 GPCs display stemness expression and extensive self-renewal.Supplementary Fig. S2. NNI-8 orthotopic xenograft recapitulates patient tumor pathophysiology
Supplementary Figure Legend from Bevacizumab-Induced Alterations in Vascular Permeability and Drug Delivery: A Novel Approach to Augment Regional Chemotherapy for In-Transit Melanoma
Authors: Turley Ryan S. , Fontanella Andrew N. , Padussis James C. , Toshimitsu Hiroaki , Tokuhisa Yoshihiro , Cho Eugenia H. , Hanna Gabi , Beasley Georgia M. , Augustine Christina K. , Dewhirst Mark W. , Tyler Douglas S.
Published: April 2023

PDF file, 74KB.
Supplementary Table 3 from Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin
Authors: Tarhini Ahmad A. , Frankel Paul , Margolin Kim A. , Christensen Scott , Ruel Christopher , Shipe-Spotloe Janice , Gandara David R. , Chen Alice , Kirkwood John M.
Published: April 2023

PDF file - 17K
Supplementary Figure 1 from ON 01910.Na Is Selectively Cytotoxic for Chronic Lymphocytic Leukemia Cells through a Dual Mechanism of Action Involving PI3K/AKT Inhibition and Induction of Oxidative Stress
Authors: Chapman Colby M. , Sun Xiameng , Roschewski Mark , Aue Georg , Farooqui Mohamed , Stennett Lawrence , Gibellini Federica , Arthur Diane , Pérez-Galán Patricia , Wiestner Adrian
Published: April 2023

PDF file - 69K
Supplementary Methods, Figure Legends 1-4 from CPTH6, a Thiazole Derivative, Induces Histone Hypoacetylation and Apoptosis in Human Leukemia Cells
Authors: Trisciuoglio Daniela , Ragazzoni Ylenia , Pelosi Andrea , Desideri Marianna , Carradori Simone , Gabellini Chiara , Maresca Giovanna , Nescatelli Riccardo , Secci Daniela , Bolasco Adriana , Bizzarri Bruna , Cavaliere Chiara , D'Agnano Igea , Filetici Patrizia , Ricci-Vitiani Lucia , Rizzo Maria Giulia , Del Bufalo Donatella
Published: April 2023

PDF file - 138K
Supplementary Figure Legends 1-4 from Proximal Tubular Secretion of Creatinine by Organic Cation Transporter OCT2 in Cancer Patients
Authors: Ciarimboli Giuliano , Lancaster Cynthia S. , Schlatter Eberhard , Franke Ryan M. , Sprowl Jason A. , Pavenstädt Hermann , Massmann Vivian , Guckel Denise , Mathijssen Ron H. J. , Yang Wenjian , Pui Ching-Hon , Relling Mary V. , Herrmann Edwin , Sparreboom Alex
Published: April 2023

PDF file - 64K
Supplementary Data from Engrailed-2 (EN2): A Tumor Specific Urinary Biomarker for the Early Diagnosis of Prostate Cancer
Authors: Morgan Richard , Boxall Angela , Bhatt Aagna , Bailey Michael , Hindley Richard , Langley Stephen , Whitaker Hayley C. , Neal David E. , Ismail Mohammed , Whitaker Hamish , Annels Nicola , Michael Agnieszka , Pandha Hardev
Published: April 2023

Supplementary Figures S1-S3.
Supplementary Table 1 from Stem Cell Pathways Contribute to Clinical Chemoresistance in Ovarian Cancer
Authors: Steg Adam D. , Bevis Kerri S. , Katre Ashwini A. , Ziebarth Angela , Dobbin Zachary C. , Alvarez Ronald D. , Zhang Kui , Conner Michael , Landen Charles N.
Published: April 2023

PDF file - 58K
Supplementary Figures 1-2 from HDL of Patients with Type 2 Diabetes Mellitus Elevates the Capability of Promoting Breast Cancer Metastasis
Authors: Pan Bing , Ren Hui , He Yubin , Lv Xiaofeng , Ma Yijing , Li Jing , Huang Li , Yu Baoqi , Kong Jian , Niu Chenguang , Zhang Youyi , Sun Wen-bing , Zheng Lemin
Published: April 2023

PDF file - 270K
Supplementary Table 5 from Combination of a Novel Gene Expression Signature with a Clinical Nomogram Improves the Prediction of Survival in High-Risk Bladder Cancer
Authors: Riester Markus , Taylor Jennifer M. , Feifer Andrew , Koppie Theresa , Rosenberg Jonathan E. , Downey Robert J. , Bochner Bernard H. , Michor Franziska
Published: April 2023

XLS file - 553K
Supplementary Table 4 from Combination of a Novel Gene Expression Signature with a Clinical Nomogram Improves the Prediction of Survival in High-Risk Bladder Cancer
Authors: Riester Markus , Taylor Jennifer M. , Feifer Andrew , Koppie Theresa , Rosenberg Jonathan E. , Downey Robert J. , Bochner Bernard H. , Michor Franziska
Published: April 2023

XLS file - 2.8MB
Supplementary Table 2 from Detection of TIMP3 Promoter Hypermethylation in Salivary Rinse as an Independent Predictor of Local Recurrence-Free Survival in Head and Neck Cancer
Authors: Sun Wenyue , Zaboli David , Wang Hao , Liu Yan , Arnaoutakis Demetri , Khan Tanbir , Khan Zubair , Koch Wayne M. , Califano Joseph A.
Published: April 2023

PDF file - 68K, Association of each marker individually with disease-free survival, adjusted for other patient and clinical characteristics of age, HPV, primary tumor site, and pathologic tumor stage.
Supplementary Table 2 from High ALK Receptor Tyrosine Kinase Expression Supersedes ALK Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma
Authors: Schulte Johannes H. , Bachmann Hagen S. , Brockmeyer Bent , DePreter Katleen , Oberthür André , Ackermann Sandra , Kahlert Yvonne , Pajtler Kristian , Theissen Jessica , Westermann Frank , Vandesompele Jo , Speleman Frank , Berthold Frank , Eggert Angelika , Brors Benedikt , Hero Barbara , Schramm Alexander , Fischer Matthias
Published: April 2023

XLS file - 25K
Supplementary Methods from PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity Is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer
Authors: Herzog Amanda , Bian Yansong , Vander Broek Robert , Hall Bradford , Coupar Jamie , Cheng Hui , Sowers Anastasia L. , Cook John D. , Mitchell James B. , Chen Zhong , Kulkarni Ashok B. , Van Waes Carter
Published: April 2023

PDF file - 160K
Supplementary Figure 5 from Galectin-1 Promotes Lung Cancer Progression and Chemoresistance by Upregulating p38 MAPK, ERK, and Cyclooxygenase-2
Authors: Chung Ling-Yen , Tang Shye-Jye , Sun Guang-Huan , Chou Teh-Ying , Yeh Tien-Shun , Yu Sung-Liang , Sun Kuang-Hui
Published: April 2023

PDF file, 155KB, Tissue microarray data.
Supplementary Figure 4 from Galectin-1 Promotes Lung Cancer Progression and Chemoresistance by Upregulating p38 MAPK, ERK, and Cyclooxygenase-2
Authors: Chung Ling-Yen , Tang Shye-Jye , Sun Guang-Huan , Chou Teh-Ying , Yeh Tien-Shun , Yu Sung-Liang , Sun Kuang-Hui
Published: April 2023

PDF file, 113KB, Gal-1 knockdown in PC-9.
Supplementary Figure S3 from The IL-18 Antagonist IL-18–Binding Protein Is Produced in the Human Ovarian Cancer Microenvironment
Authors: Carbotti Grazia , Barisione Gaia , Orengo Anna Maria , Brizzolara Antonella , Airoldi Irma , Bagnoli Marina , Pinciroli Patrizia , Mezzanzanica Delia , Centurioni Maria Grazia , Fabbi Marina , Ferrini Silvano
Published: April 2023

Supplementary Figure S3 - PDF file 9497K, A: Immunochemical analysis of IL-18BP expression in cells from EOC ascites. Double staining with anti-IL-18BP (red, rabbit mAb clone EP1088Y, Epitomics) and anti-macrophage (brown, mAb HAM-56, Ventana Medical Systems) antibodies is shown. Biotin-labeled goat anti-rabbit followed by alkaline phosphatase-conjugated streptavidin and peroxidase-conjugated anti-mouse (BioSpa) were used as secondary antibodies. Fast Red and DAB (Sigma) served as substrates. Bar=100�m. Some of the cells stained by the anti-macrophage Ab were also stained by anti-IL-18BP Ab (see enlarged inset). However, the brightest IL-18BP positive cells were negative for the anti-macrophage Ab. B: Two-color immunofluorescence analysis of IL-18BP protein versus leukocyte surface markers expression in cells from EOC ascites. Numbers indicate the % of cells in each quadrant. IL-18BP positive cells were CD13 positive and CD14 low or negative (as all the CD14 positive cells were within the CD13 positive population: lower right panel). FITC: fluorescein isothiocyanate; APC: allophycocyanin; PE: phycoerythrin. CD14APC and CD14PE were from Miltenyi Biotec, CD13PE from BD Pharmingen and NKp46PE from Beckman Coulter. Cells were analyzed on a FACSCalibur (Becton Dickinson) flow cytometer
Supplementary Figure 8 from Sequence Dependence of MEK Inhibitor AZD6244 Combined with Gemcitabine for the Treatment of Biliary Cancer
Authors: Xu Junyao , Knox Jennifer J. , Ibrahimov Emin , Chen Eric , Serra Stefano , Tsao Ming , Cao Pinjiang , Vines Douglass , Green David E. , Metran-Nascente Cristiane , McNamara Mairead G. , Hedley David W.
Published: April 2023

PDF file - 111K, Effects of the combination of AZD6244 with gemcitabine plus cisplatin
Supplementary Figure 4 from Sequence Dependence of MEK Inhibitor AZD6244 Combined with Gemcitabine for the Treatment of Biliary Cancer
Authors: Xu Junyao , Knox Jennifer J. , Ibrahimov Emin , Chen Eric , Serra Stefano , Tsao Ming , Cao Pinjiang , Vines Douglass , Green David E. , Metran-Nascente Cristiane , McNamara Mairead G. , Hedley David W.
Published: April 2023

PDF file - 319K, Inhibitory effect of sequential treatments with AZD6244 and gemcitabine on cell proliferation in TFK-1 cells
Supplementary Figure 5 from Iron Deprivation Suppresses Hepatocellular Carcinoma Growth in Experimental Studies
Authors: Ba Qian , Hao Miao , Huang He , Hou Junmei , Ge Shichao , Zhang Zhuzhen , Yin Jun , Chu Ruiai , Jiang Hualiang , Wang Fudi , Chen Kaixian , Liu Hong , Wang Hui
Published: April 2023

PDF file - 9.4MB
Supplementary Figure 3 from Sequence Dependence of MEK Inhibitor AZD6244 Combined with Gemcitabine for the Treatment of Biliary Cancer
Authors: Xu Junyao , Knox Jennifer J. , Ibrahimov Emin , Chen Eric , Serra Stefano , Tsao Ming , Cao Pinjiang , Vines Douglass , Green David E. , Metran-Nascente Cristiane , McNamara Mairead G. , Hedley David W.
Published: April 2023

PDF file - 161K, Time course of recovery of cell cycle phase distribution and proliferation following AZD6244 treatment in vitro
Supplementary Figure 1 from Iron Deprivation Suppresses Hepatocellular Carcinoma Growth in Experimental Studies
Authors: Ba Qian , Hao Miao , Huang He , Hou Junmei , Ge Shichao , Zhang Zhuzhen , Yin Jun , Chu Ruiai , Jiang Hualiang , Wang Fudi , Chen Kaixian , Liu Hong , Wang Hui
Published: April 2023

PDF file - 3.7MB
Supplementary Figure 3 from Targeting Stat3 Abrogates EGFR Inhibitor Resistance in Cancer
Authors: Sen Malabika , Joyce Sonali , Panahandeh Mary , Li Changyou , Thomas Sufi M. , Maxwell Jessica , Wang Lin , Gooding William E. , Johnson Daniel E. , Grandis Jennifer R.
Published: April 2023

PDF file, 37K, STAT3 decoy inhibits tumor growth in vivo of TKI resistant HNSCC xenografts.
Supplementary Figure 1 from Targeting Stat3 Abrogates EGFR Inhibitor Resistance in Cancer
Authors: Sen Malabika , Joyce Sonali , Panahandeh Mary , Li Changyou , Thomas Sufi M. , Maxwell Jessica , Wang Lin , Gooding William E. , Johnson Daniel E. , Grandis Jennifer R.
Published: April 2023

PDF file, 16K, Comparable EC50 values for erlotinib in sensitive and cetuximab resistant bladder cancer cell lines.
Supplementary Figure 2 from Stichoposide C Induces Apoptosis through the Generation of Ceramide in Leukemia and Colorectal Cancer Cells and Shows In Vivo Antitumor Activity
Authors: Yun Seong-Hoon , Park Eun-Seon , Shin Sung-Won , Na Yong-Woo , Han Jin-Yeong , Jeong Jin-Sook , Shastina Valeria V. , Stonik Valentin A. , Park Joo-In , Kwak Jong-Young
Published: April 2023

PDF file - 2.3MB, Treatment of colorectal cancer cells with STC leads to generation of ceramide through the activation of acid SMase and neutral SMase. (A and B) CT-26 cells (1 �~ 105 cells/well) were incubated with STC in the presence or absence of desipramine or GW4869 for 24 h. After treatment, cells were fixed and permeabilized. Then, samples were stained with FITC-anti-ceramide and (A) PE-anti-acid SMase or (B) PE-anti-neutral SMase antibodies. Left panel shows the low magnifications of CT-26 cells treated as in A. Right panel shows higher magnifications of CT-26 cells treated as in A. (C and D) SNU-C4 cells (1 �~ 105 cells/well) were incubated with STC in the presence or absence of desipramine or GW4869 for 24 h. After treatment, cells were fixed and permeabilized. Then, samples were stained with FITC-anti-ceramide and (C) PE-anti-acid SMase or (D) PE-anti-neutral SMase antibodies. Left panel shows the low magnifications of SNU-C4 cells treated as in C. Right panel shows higher magnifications of SNU-C4 cells treated as in C.
Supplementary Figure 1, Tables 1-3 from miRNA Expression Profiling Enables Risk Stratification in Archived and Fresh Neuroblastoma Tumor Samples
Authors: De Preter Katleen , Mestdagh Pieter , Vermeulen Joëlle , Zeka Fjoralba , Naranjo Arlene , Bray Isabella , Castel Victoria , Chen Caifu , Drozynska Elzbieta , Eggert Angelika , Hogarty Michael D. , Iżycka-Swieszewska Ewa , London Wendy B. , Noguera Rosa , Piqueras Marta , Bryan Kenneth , Schowe Benjamin , van Sluis Peter , Molenaar Jan J. , Schramm Alexander , Schulte Johannes H. , Stallings Raymond L. , Versteeg Rogier , Laureys Geneviève , Van Roy Nadine , Speleman Frank , Vandesompele Jo
Published: April 2023

PDF file - 132K
Related Article from Will Hsp90 Inhibitors Prove Effective in BRAF-Mutant Melanomas?
Authors: Catalanotti Federica , Solit David B.
Published: April 2023

Related Article from Will Hsp90 Inhibitors Prove Effective in BRAF-Mutant Melanomas?
Supplementary Figure 5 from Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor
Authors: Dosset Magalie , Godet Yann , Vauchy Charline , Beziaud Laurent , Lone Yu Chun , Sedlik Christine , Liard Christelle , Levionnois Emeline , Clerc Bertrand , Sandoval Federico , Daguindau Etienne , Wain-Hobson Simon , Tartour Eric , Langlade-Demoyen Pierre , Borg Christophe , Adotévi Olivier
Published: April 2023

PDF file - 26K, UCP2 specific CD4 T cells recognize the mTERT-derived counterpart peptide p568
Supplementary Figure 7 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy
Authors: Kienast Yvonne , Klein Christian , Scheuer Werner , Raemsch Romi , Lorenzon Erica , Bernicke Dirk , Herting Frank , Yu Sidney , The Huynh Hung , Martarello Laurent , Gassner Christian , Stubenrauch Kay-Gunnar , Munro Kate , Augustin Hellmut G. , Thomas Markus
Published: April 2023

PDF file 69K, Ang-2 induced VEGFR-2 upregulation
Supplementary Figure Legend 1 from Overexpression of ZEB2 at the Invasion Front of Colorectal Cancer Is an Independent Prognostic Marker and Regulates Tumor Invasion In Vitro
Authors: Kahlert Christoph , Lahes Saleh , Radhakrishnan Praveen , Dutta Shamik , Mogler Carolin , Herpel Esther , Brand Karsten , Steinert Gunnar , Schneider Martin , Mollenhauer Martin , Reissfelder Christoph , Klupp Fee , Fritzmann Johannes , Wunder Christina , Benner Axel , Kloor Matthias , Huth Cathrin , Contin Pietro , Ulrich Alexis , Koch Moritz , Weitz Jürgen
Published: April 2023

PDF file - 38K
Supplementary Figure 5 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy
Authors: Kienast Yvonne , Klein Christian , Scheuer Werner , Raemsch Romi , Lorenzon Erica , Bernicke Dirk , Herting Frank , Yu Sidney , The Huynh Hung , Martarello Laurent , Gassner Christian , Stubenrauch Kay-Gunnar , Munro Kate , Augustin Hellmut G. , Thomas Markus
Published: April 2023

PDF file 138K, Ex vivo mode of action analysis of Ang-2-VEGF-A inhibition
Supplementary Figure 1 from Overexpression of ZEB2 at the Invasion Front of Colorectal Cancer Is an Independent Prognostic Marker and Regulates Tumor Invasion In Vitro
Authors: Kahlert Christoph , Lahes Saleh , Radhakrishnan Praveen , Dutta Shamik , Mogler Carolin , Herpel Esther , Brand Karsten , Steinert Gunnar , Schneider Martin , Mollenhauer Martin , Reissfelder Christoph , Klupp Fee , Fritzmann Johannes , Wunder Christina , Benner Axel , Kloor Matthias , Huth Cathrin , Contin Pietro , Ulrich Alexis , Koch Moritz , Weitz Jürgen
Published: April 2023

PDF file - 492K
Supplementary Figure 1 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy
Authors: Kienast Yvonne , Klein Christian , Scheuer Werner , Raemsch Romi , Lorenzon Erica , Bernicke Dirk , Herting Frank , Yu Sidney , The Huynh Hung , Martarello Laurent , Gassner Christian , Stubenrauch Kay-Gunnar , Munro Kate , Augustin Hellmut G. , Thomas Markus
Published: April 2023

PDF file 169K, Schematic representation of Ang2-VEGF-A CrossMab (RO5520985) and binding properties